Answers are grounded in this paper and cite their sources.
IMiDs have been associated with some degree of renal recovery with manageable toxicity profile and should be considered especially for bortezomib-refractory patients.Treatment choices should be individualized and based on previous lines of therapy, and specific patients and disease characteristics.
No takes yet. Share an insight, caveat, or question.
Gavriatopoulou et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: